Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′- or 3′-mono-fluoro substituted, or 2′3′-di-fluoro substituted mixed linkage 2′,5′-3′,5′ CDNs.
1. A compound of Formula IB-g:
wherein R3b is —F and R4b is —OH or —O—C(═O)—C 1-14 alkyl, or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof.
2. The compound according to claim 1 , wherein the compound is
2′3′-RR-(G)(2′F-A) having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof.
3. A composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable excipient.
4. A composition comprising one or more compounds according to claim 1 and a delivery vehicle which enhances cellular uptake and/or stability of the compound.
5. The composition according to claim 4 , wherein the delivery vehicle comprises one or more agents selected from the group consisting of lipids, liposomes, interbilayer crosslinked multilamellar vesicles, biodegradeable poly(D,L-lactic-co-glycolic acid) [PLGA]-based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.
6. A composition comprising one or more compounds according to claim 1 and one or more agents selected from the group consisting of an immune checkpoint inhibitor; a Toll-like Receptor (TLR) agonist; a composition that mediates innate immune activation via TLRs, via (NOD)-like receptors (NLRs), via Retinoic acid inducible gene-based (RIG)-I-like receptors (RLRs), via C-type lectin receptors (CLRs), or via pathogen-associated molecular patterns (“PAMPs”); and a chemotherapeutic agent.
7. The composition according to claim 6 , wherein the one or more agents is an immune checkpoint inhibitor or a histone deacetylase inhibitor.
8. The composition according to claim 3 , further comprising one or more antigens selected for purposes of inducing an immune response against the antigen(s) when the composition is administered to an individual, optionally wherein the antigen is one or more recombinant protein antigens, wherein the recombinant protein antigen is a neoantigen, is related to an infectious disease, is related to a malignancy, or is related to an allergan.
9. A method for treating an individual suffering from cancer, comprising:
administering to the individual an effective amount of the compound according to claim 1 .
10. The method according to claim 9 , wherein the administration is intravenous, subcutaneous, intramuscular, intradermal, oral, mucosal, vaginal, cervical, peri-tumoral, intra-tumoral, or directly into the tumor-draining lymph node(s).
11. A method of treating a disease in an individual, comprising: administering to the individual in need thereof i) an effective amount of the compound according to claim 1 ; and ii) an effective amount of one or more therapeutic antibodies that induce antibody-dependent cellular cytotoxicity, wherein the disease is selected from the group consisting of a cancer, acute rejection of an organ transplant, Type I diabetes mellitus, rheumatoid arthritis, psoriasis, Crohn's disease, restenosis and allergic asthma.
12. The compound according to claim 1 , wherein the compound is 2′3′-RR-(3′decanoyl-O-G)(2′F-A) having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof.